The pharmaceutical companies Biogen and Eisai are developing a new drug to slow the rate of cognitive decline among patients with Alzheimer's disease, according to the New York Times. The drug, called lecanemab, reduced cognitive decline by 27 percent in a recent clinical trial. Previously, Biogen released the controversial drug Aduhelm, widely considered a commercial failure after Medicare restricted its coverage.
Related Posts
National Hispanic Heritage Month begins September 15
It is unusual to begin a month-long observance mid-month, but there’s good reason for National Hispanic Heritage Month to begin on the 15th. Five Latin…
The Adam’s apple: What it is; what it does
The Adam’s apple is the lump of cartilage that protrudes from the throat. “Adam’s apple,” as described by Merriam-Webster, is a derivative of a Latin term…
Scientists study thunderstorm asthma
Walking through a field of weeds might give some an asthma attack, but a thunderstorm? According to the journal PLOS ONE, researchers in Australia think…